Significance of IASLC/ATS/ERS classification for early-stage lung adenocarcinoma patients in predicting benefit from adjuvant chemotherapy

Yusuke Takahashi; Takashi Eguchi; Sarina Bains; Prasad S. Adusumilli

doi:10.3978/j.issn.2305-5839.2015.10.40

Significance of IASLC/ATS/ERS classification for early-stage lung adenocarcinoma patients in predicting benefit from adjuvant chemotherapy

Yusuke Takahashi, Takashi Eguchi, Sarina Bains, Prasad S. Adusumilli

Research output: Contribution to journal › Editorial › peer-review

Original language	English
Article number	66
Journal	Annals of Translational Medicine
Volume	4
Issue number	4
DOIs	https://doi.org/10.3978/j.issn.2305-5839.2015.10.40
Publication status	Published - 2016 Feb
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.3978/j.issn.2305-5839.2015.10.40

Cite this

@article{7f012b7d8d5448858e4648ba0f2f7810,

title = "Significance of IASLC/ATS/ERS classification for early-stage lung adenocarcinoma patients in predicting benefit from adjuvant chemotherapy",

author = "Yusuke Takahashi and Takashi Eguchi and Sarina Bains and Adusumilli, {Prasad S.}",

note = "Funding Information: This work is supported by grants from the National Institutes of Health (U54 CA137788 and P30 CA008748); the US Department of Defense (LC110202); and Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant (SU2C-AACR-DT1012). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.",

year = "2016",

month = feb,

doi = "10.3978/j.issn.2305-5839.2015.10.40",

language = "English",

volume = "4",

journal = "Annals of Translational Medicine",

issn = "2305-5839",

publisher = "AME Publishing Company",

number = "4",

}

TY - JOUR

T1 - Significance of IASLC/ATS/ERS classification for early-stage lung adenocarcinoma patients in predicting benefit from adjuvant chemotherapy

AU - Takahashi, Yusuke

AU - Eguchi, Takashi

AU - Bains, Sarina

AU - Adusumilli, Prasad S.

N1 - Funding Information: This work is supported by grants from the National Institutes of Health (U54 CA137788 and P30 CA008748); the US Department of Defense (LC110202); and Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant (SU2C-AACR-DT1012). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.

PY - 2016/2

Y1 - 2016/2

UR - http://www.scopus.com/inward/record.url?scp=85006207160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006207160&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2305-5839.2015.10.40

DO - 10.3978/j.issn.2305-5839.2015.10.40

M3 - Editorial

AN - SCOPUS:85006207160

SN - 2305-5839

VL - 4

JO - Annals of Translational Medicine

JF - Annals of Translational Medicine

IS - 4

M1 - 66

ER -

Significance of IASLC/ATS/ERS classification for early-stage lung adenocarcinoma patients in predicting benefit from adjuvant chemotherapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this